Merck & Co
Merck and Daiichi partner on a $5.5 billion deal for cancer therapy development
20 Oct 2023
The American pharmaceutical company Merck will start a joint venture with Daiichi Sankyo to develop three of its candidate cancer drugs.
EU conditional nod for Merck's $17-bn purchase of Sigma-Aldrich
16 Jun 2015
Sigma-Aldrich is a life science and technology company that manufactures and distributes more than 230,000 chemicals, biochemicals and other essential products globally to research and applied labs as well as in industrial and commercial markets
Merck & Co to buy Cubist Pharmaceuticals for $8.4 bn
10 Dec 2014
Merck expects the acquisition to add more than $1 billion of revenue after closing in the first quarter, but will be neutral to non-GAAP earnings per share until 2016
Merck & Co in talks to buy Cubist Pharmaceuticals for more than $7 bn
06 Dec 2014
Cubist Pharmaceuticals develops drugs for potentially life-threatening infections caused by dangerous bacteria categorised as serious and urgent public health threats
Merck oncology drug wins ‘breakthrough’ classification by US regulators
28 Oct 2014
Keytruda, Merck & Co's flagship new drug, forms part of a new generation of oncology treatments that use the body’s own immune system to attack and destroy tumours
Merck & Co to sell consumer care business to Germany's Bayer for $14.2 bn
06 May 2014
The deal, which will make Bayer the second-biggest over-the-counter drugs (OTC) maker after Johnson & Johnson, is the largest in the German healthcare industry after Bayer outbid Merck to acquire Schering in 2006 for $21.5 billion
Bayer offers to swap cash and animal health unit for Merck's consumer healthcare
30 Apr 2014
German healthcare major Bayer AG has offered to swap its animal health unit and also pay some cash in exchange for Merck & Co's consumer healthcare business
Bayer, Novartis, Reckitt Benckiser, P&G in fray for Merck & Co's consumer healthcare unit
20 Feb 2014
Bayer, Novartis, Reckitt Benckiser, and Procter & Gamble are among the companies that are exploring a deal to buy Merck &Co's consumer healthcare unit
Merck & Co to buy back $5-bn worth stock
22 May 2013
Merck, the second-largest US drugmaker, will repurchase about 99.5 million shares from Goldman Sachs at current market prices
Delhi HC refuses interim relief to Merck over Glenmark drug
05 Apr 2013
Glenmark said the US drug firm has no patent rights over ‘Sitagliptin Phosphate’, which is used in its anti-diabetes drugs Zita and Zita-Met
Merck & Co forecast profit decline for 2013
02 Feb 2013
Featured articles
Lighter than air, yet very, very powerful
By Kiron Kasbekar | 03 Jan 2024
In March 2013 Chinese scientists pulled off a remarkable feat. They created the world’s lightest aerogel. Tipping the scales at a mere 0.16 milligrams per cubic centimeter – that’s a sixth of the weight of air!
COP28 explained: A closer look at COP28's climate change solutions
By Aniket Gupta | 27 Dec 2023
The 28th United Nations Climate Change Conference, also known as COP28, took place from 30th November 2023, to 13th December 2023, at Expo City in Dubai, United Arab Emirates.
What is a Ponzi scheme?
By Aniket Gupta | 06 Dec 2023
Ponzi schemes have long captivated the public imagination, drawing unsuspecting investors into a web of illusion and deception.
The Rise and Rise of HDFC Bank
03 Jul 2023
HDFC, which surged ahead of global majors like HSBC Holdings Plc and Citigroup Inc and left Indian peers like State Bank of India and ICICI Bank in market capitalisation, now ranks fourth largest among the world’s most valuable banks, after JPMorgan Chase & Co, Industrial and Commercial Bank of China Ltd and Bank of America Corp
India’s Millet Revolution To Enrich Global Food Basket
02 Apr 2023
Millets, a healthier and cheaper substitute to wheat and rice, are indigenous to many parts of the world, especially in the semiarid tropics of Asia and Africa, and offers a big scope for expanding production and consumption in the foodgrain deficient African continent
Market predator Hindenburg preys on Adani stock
06 Mar 2023
Almost a month after the damning report of short-seller Hindenburg Research on the Adani Group that claimed that the seven stocks within the group were about 85 per cent overvalued, one of the group's stocks, Adani Total Gas, closed at Rs835 on the BSE, down nearly 79 per cent from its 24 January level, almost close to reaching that valuation
